Allergan reported net sales of $1,467.4 million for the second quarter, up by 4.8 percent from the year-ago period, in spite of the strong U.S. dollar. On a constant-currency basis, the rate of increase was 8.7 percent. Sales of specialty pharmaceuticals grew by 5 percent, or 8.8 percent on a constant-currency basis. The increase for medical devices was 4 percent, or 8.3 percent in constant currencies. For the full year, Allergan expects total sales of between $5,650 million and $5,800 million.